


8/20/99


In the Claims:

Cancel claims 9 and 10 without prejudice or disclaimer.

1. A compound according to claim 13, having a formula selected from the group consisting of:






and




549/487,488
514/461

or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.

2. A compound according to claim 13, having a formula selected from the group consisting of:




and




or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.

3. A compound according to claim 13, having the formula:




or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.

4. A compound according to claim 13, having a formula selected from the group consisting of:




and




or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.

5. A compound according to claim 13, having the formula:




or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.

~~A1~~
Sub
B1




and



R.1.126

~~13.~~ A compound represented by the formula



wherein:

R₃ is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH₂OR, OR, or C(O)OR, COR, where R is selected from the group consisting of hydrogen, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, and heteroaryl, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12;

R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH₂OR, OR, and C(O)OR, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12;

~~R₆ is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, COR, CH₂OR, OR, or C(O)OR, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12.~~

provided that R_3 , R_4 , R_5 , and R_6 are not all hydrogen;

R_7 is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH_2OR , OR , or $C(O)OR$, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12; or

R_6 and R_7 taken together with the atoms to which they are bonded form an optionally substituted 5- or 6-membered ring optionally having up to four heteroatoms selected from O, N, and S;

R_8 is a lipophilic moiety selected from substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH_2OR , OR , and $C(O)OR$, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 6 to 20; and

R_9 is hydrogen or substituted or unsubstituted alkyl;

or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.

A2


12

~~14~~ A compound or pharmaceutically acceptable salt according to claim 13.

13

~~15~~ A pharmaceutical composition comprising;

(a) a therapeutically effective amount of a compound represented by the formula



wherein:

R_3 is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH_2OR , OR , or $C(O)OR$, COR , where R is selected from the group consisting of hydrogen, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, and heteroaryl, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12;

R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl,

CH_2OR , OR , and C(O)OR , where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12;

R_6 is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, COR , CH_2OR , OR , or C(O)OR , where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12,

provided that R_3 , R_4 , R_5 , and R_6 are not all hydrogen;

R_7 is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH_2OR , OR , or C(O)OR , where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12; or

R_6 and R_7 taken together with the atoms to which they are bonded form an optionally substituted 5- or 6-membered ring optionally having up to four heteroatoms selected from O , N , and S ;

R_8 is a lipophilic moiety selected from substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH_2OR , OR , and C(O)OR , where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 6 to 20; and

R_9 is hydrogen or substituted or unsubstituted alkyl;


or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof;

and

(b) a pharmaceutically acceptable carrier or diluent.

14

16 A method for regulating the secretion of gonadotropins in mammals, comprising administering to a mammal in need of such regulation, a therapeutically effective amount of a compound represented by the formula



wherein:

R₃ is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH₂OR, OR, or C(O)OR, COR, where R is selected from the group consisting of hydrogen, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, and heteroaryl, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12;

R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH₂OR, OR, and C(O)OR, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12;

A2
R₆ is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, COR, CH₂OR, OR, or C(O)OR, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12,

provided that R₃, R₄, R₅, and R₆ are not all hydrogen;

R₇ is hydrogen, halogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH₂OR, OR, or C(O)OR, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 1 to 12; or

R₆ and R₇ taken together with the atoms to which they are bonded form an optionally substituted 5- or 6-membered ring optionally having up to four heteroatoms selected from O, N, and S;

R₈ is a lipophilic moiety selected from substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, CH₂OR, OR, and C(O)OR, where R is as defined above, and where the total number of carbon atoms present (not including any optional substituents) ranges from 6 to 20; and

R₉ is hydrogen or substituted or unsubstituted alkyl;

or a pharmaceutically acceptable salt, multimer, prodrug, or active metabolite thereof.